208 related articles for article (PubMed ID: 35584864)
1. Deconvolution of malignant pleural effusions immune landscape unravels a novel macrophage signature associated with worse clinical outcome in lung adenocarcinoma patients.
Bruschini S; Pallocca M; Sperandio E; D'Ambrosio L; Ascenzi F; De Vitis C; Salvati V; Esposito A; Di Martino S; De Nicola F; Paolini F; Fattore L; Alessandrini G; Facciolo F; Foddai ML; Bassi M; Venuta F; D'Ascanio M; Ricci A; D' Andrilli A; Napoli C; Aurisicchio L; Fanciulli M; Rendina EA; Ciliberto G; Mancini R
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35584864
[TBL] [Abstract][Full Text] [Related]
2. Human lung adenocarcinoma cell cultures derived from malignant pleural effusions as model system to predict patients chemosensitivity.
Roscilli G; De Vitis C; Ferrara FF; Noto A; Cherubini E; Ricci A; Mariotta S; Giarnieri E; Giovagnoli MR; Torrisi MR; Bergantino F; Costantini S; Fenizia F; Lambiase M; Aurisicchio L; Normanno N; Ciliberto G; Mancini R
J Transl Med; 2016 Feb; 14():61. PubMed ID: 26928703
[TBL] [Abstract][Full Text] [Related]
3. Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma.
Yang L; He YT; Dong S; Wei XW; Chen ZH; Zhang B; Chen WD; Yang XR; Wang F; Shang XM; Zhong WZ; Wu YL; Zhou Q
J Immunother Cancer; 2022 Jan; 10(2):. PubMed ID: 35140113
[TBL] [Abstract][Full Text] [Related]
4. Migrated T lymphocytes into malignant pleural effusions: an indicator of good prognosis in lung adenocarcinoma patients.
Nieto JC; Zamora C; Porcel JM; Mulet M; Pajares V; Muñoz-Fernandez AM; Calvo N; Espinosa I; Pascual-García M; Bielsa S; Vidal S
Sci Rep; 2019 Feb; 9(1):2996. PubMed ID: 30816121
[TBL] [Abstract][Full Text] [Related]
5. Exploratory pilot study to characterize the immune landscapes of malignant pleural effusions and their corresponding primary tumors from patients with breast carcinoma and lung adenocarcinoma.
Laberiano-Fernandez C; Gan Q; Wang SM; Tamegnon A; Wistuba I; Yoon E; Roy-Chowdhuri S; Parra ER
J Am Soc Cytopathol; 2024; 13(3):161-173. PubMed ID: 38519275
[TBL] [Abstract][Full Text] [Related]
6. EGFR Mutation Status in Lung Adenocarcinoma-Associated Malignant Pleural Effusion and Efficacy of EGFR Tyrosine Kinase Inhibitors.
Yang J; Lee OJ; Son SM; Woo CG; Jeong Y; Yang Y; Kwon J; Lee KH; Han HS
Cancer Res Treat; 2018 Jul; 50(3):908-916. PubMed ID: 28934846
[TBL] [Abstract][Full Text] [Related]
7. CD39 identifies a specific CD8 + T cell population in lung adenocarcinoma-related metastatic pleural effusion.
Lv LL; Wang HB; Zhang YX; Zhai JW; Shen Y; Qu QX; Chen C
BMC Immunol; 2023 Dec; 24(1):53. PubMed ID: 38087217
[TBL] [Abstract][Full Text] [Related]
8. The heterogeneous immune landscape between lung adenocarcinoma and squamous carcinoma revealed by single-cell RNA sequencing.
Wang C; Yu Q; Song T; Wang Z; Song L; Yang Y; Shao J; Li J; Ni Y; Chao N; Zhang L; Li W
Signal Transduct Target Ther; 2022 Aug; 7(1):289. PubMed ID: 36008393
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the alternative splicing landscape in lung adenocarcinoma reveals novel prognosis signature associated with B cells.
Shao MM; Zhai K; Huang ZY; Yi FS; Zheng SC; Liu YL; Qiao X; Chen QY; Wang Z; Shi HZ
PLoS One; 2023; 18(7):e0279018. PubMed ID: 37432957
[TBL] [Abstract][Full Text] [Related]
10. Spheres derived from lung adenocarcinoma pleural effusions: molecular characterization and tumor engraftment.
Mancini R; Giarnieri E; De Vitis C; Malanga D; Roscilli G; Noto A; Marra E; Laudanna C; Zoppoli P; De Luca P; Affuso A; Ruco L; Di Napoli A; Mesiti G; Aurisicchio L; Ricci A; Mariotta S; Pisani L; Andreetti C; Viglietto G; Rendina EA; Giovagnoli MR; Ciliberto G
PLoS One; 2011; 6(7):e21320. PubMed ID: 21789168
[TBL] [Abstract][Full Text] [Related]
11. Transcriptomic FHIT
Brisebarre A; Ancel J; Ponchel T; Loeffler E; Germain A; Dalstein V; Dormoy V; Durlach A; Delepine G; Deslée G; Polette M; Nawrocki-Raby B
Front Immunol; 2022; 13():1058531. PubMed ID: 36544755
[TBL] [Abstract][Full Text] [Related]
12. ERCC6L is a biomarker and therapeutic target for non-small cell lung adenocarcinoma.
Hou G; Lu Z; Bi Y; Deng J; Yang X
Med Oncol; 2022 Feb; 39(5):51. PubMed ID: 35150321
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneity of tumor immune microenvironment in malignant and metastatic change in LUAD is revealed by single-cell RNA sequencing.
Wang H; Han G; Chen J
Aging (Albany NY); 2023 Jun; 15(12):5339-5354. PubMed ID: 37335089
[TBL] [Abstract][Full Text] [Related]
14. Identification of the cell cycle characteristics of non-small cell lung cancer and its relationship with tumor immune microenvironment, cell death pathways, and metabolic reprogramming.
Cao S; Xiao S; Zhang J; Li S
Front Endocrinol (Lausanne); 2023; 14():1147366. PubMed ID: 37091844
[TBL] [Abstract][Full Text] [Related]
15. Superiority and clinical significance of Lunx mRNA in the diagnosis of malignant pleural effusion caused by pulmonary carcinoma.
Tang Y; Xu L
J Exp Clin Cancer Res; 2013 Jun; 32(1):37. PubMed ID: 23759037
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 Expression of Tumor Cells, Macrophages, and Immune Cells in Non-Small Cell Lung Cancer Patients with Malignant Pleural Effusion.
Tseng YH; Ho HL; Lai CR; Luo YH; Tseng YC; Whang-Peng J; Lin YH; Chou TY; Chen YM
J Thorac Oncol; 2018 Mar; 13(3):447-453. PubMed ID: 29246835
[TBL] [Abstract][Full Text] [Related]
17. Malignant pleural effusion supernatants are substitutes for metastatic pleural tumor tissues in EGFR mutation test in patients with advanced lung adenocarcinoma.
Liu D; Lu Y; Hu Z; Wu N; Nie X; Xia Y; Han Y; Li Q; Zhu G; Bai C
PLoS One; 2014; 9(2):e89946. PubMed ID: 24587142
[TBL] [Abstract][Full Text] [Related]
18. Comparative study of EGFR mutations detected in malignant pleural effusion, plasma and tumor tissue in patients with adenocarcinoma of the lung.
Wang S; Chen H; Zhong J; Qin H; Bai H; Zhao J; Wang J
Lung Cancer; 2019 Sep; 135():116-122. PubMed ID: 31446983
[TBL] [Abstract][Full Text] [Related]
19. Upregulation of soluble B7-H3 in NSCLC-derived malignant pleural effusion: A potential diagnostic biomarker correlated with NSCLC staging.
Chen L; Zhang G; Sheng S; Zhou Q; Pan Y; Guan S
Clin Chim Acta; 2016 Jun; 457():81-5. PubMed ID: 27071700
[TBL] [Abstract][Full Text] [Related]
20.
Liu L; Wang C; Li S; Qu Y; Xue P; Ma Z; Zhang X; Bai H; Wang J
Front Immunol; 2021; 12():677169. PubMed ID: 34354701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
